Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951019 | 0.88 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3CCR2HRH3 | |
| SCHEMBL31050268 | 0.81 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3CCR2HRH3 | |
| Hydrochloric Acid SCHEMBL20563260 | 0.80 | TAAR1 (0.43) | SLC6A4SLC6A2SLC6A3SMN1; SMN2TAAR1 | |
| SCHEMBL31503518 | 0.79 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3CCR2HRH3 | |
| SCHEMBL16952861 | 0.77 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1016506 | 0.76 | CYP2A6 (0.40) | SLC6A4SLC6A2SLC6A3HRH3SMN1; SMN2 | |
| SCHEMBL10748244 | 0.74 | HSP90AA1 (0.38) | ALDH1A1TAAR1 | |
| SCHEMBL15897837 | 0.73 | SLC6A4 (0.33) | SLC6A4SLC6A2SLC6A3CCR2HRH3 | |
| SCHEMBL7820988 | 0.73 | SLC6A4 (0.34) | SLC6A4SLC6A2SLC6A3CCR2HRH3 | |
| SCHEMBL31488655 | 0.73 | SLC6A4 (0.32) | SLC6A4SLC6A2SLC6A3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665730-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12291529-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240376105-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240327404-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024169952-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376105-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | SLC6A4 933/4885SLC6A2 1912/4885SLC6A3 1273/4885 |
| US-12291529-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, IAPP | SLC6A4 933/4885SLC6A2 1912/4885SLC6A3 1273/4885 |
| US-20240327404-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | SLC6A4 933/4885SLC6A2 1912/4885SLC6A3 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.